Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesThalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients
Leukemia Research, 05/12/09
Oliveira AM et al. - The findings indicate that thalidomide therapy induces down-regulation of CXCR4 and its ligand SDF-1alpha in multiple myeloma.
Related Articles
Hyperlipidemic myeloma: review of 53 cases
Annals of Hematology, 11/25/09
Relevance Score: 94%
Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry
Acta Haematologica, 11/04/09
Relevance Score: 89%
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Journal of Clinical Oncology, 10/02/09
Relevance Score: 89%
Characteristics of Orbital Multiple Myeloma: A Case Report and Literature Review
Survey of Ophthalmology, 10/23/09
Relevance Score: 88%
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Leukemia, 10/05/09
Relevance Score: 88%
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
Blood, 11/25/09
Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation
Experimental Hematology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial
British Journal of Cancer, 11/29/09
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor